NCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT04774419 2026-02-03
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07336147 2026-01-14
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT07108270 2025-12-22
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
Phase 2 Recruiting
NCT07115927 2025-08-19
RODEO
University College, London
Phase 2 Not yet recruiting
NCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03574779 2025-07-15
OPAL
Tesaro, Inc.
Phase 2 Completed
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT07013851 2025-06-10
NADIA
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Not yet recruiting
NCT03833479 2025-05-21
ATOMICC
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Active not recruiting
NCT06278857 2024-12-03
SATELLITE
Queensland Centre for Gynaecological Cancer
Phase 2 Recruiting
NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05751629 2023-04-21
COHORT-A
Tesaro, Inc.
Phase 2 Completed
NCT05405192 2023-02-28
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
University of Miami
Phase 2 Withdrawn